Vaccitech reports positive interim data in study on immunotherapeutic for HPV infection 21-Mar-2023 By Jane Byrne Oxford UK based Vaccitech reports positive topline interim data from a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.